2023 News Archive
Friday February 17, 2023
Iveric Bio announced that the US Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The NDA has been granted priority review, meaning the FDA will act on the application within 6 months, rather than the 10 months typical under standard review.
Friday February 3, 2023
EyeArt AI System Receives EU Approval for AMD and Glaucoma Screening